Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

With blockbuster GLP-1 drugs such as Ozempic, Wegovy from Danish drug maker Novo Nordisk, and Mounjaro from American pharma ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...